Key result
Factor XIa inhibitors emerge as next-generation anticoagulants offering improved safety and expanded arterial efficacy.
Answers are grounded in this paper and cite their sources.
With the introduction of thrombin and factor Xa inhibitors to the oral anticoagulant market, significant improvements in both efficacy and safety have been achieved. Early clinical and preclinical data suggest that inhibitors of factor XIa can provide a still safer alternative, with expanded efficacy for arterial indications. This Perspective provides an overview of target rationale and details of the discovery and development of inhibitors of factor XIa as next generation antithrombotic agents.
No takes yet. Share an insight, caveat, or question.
Quan et al. (2018) conducted a review in Thrombosis / arterial indications requiring anticoagulation. Factor XIa inhibitors vs. Thrombin and factor Xa inhibitors was evaluated. Factor XIa inhibitors are reviewed as next-generation oral anticoagulants that may offer improved safety and expanded efficacy for arterial indications compared with thrombin and factor Xa inhibitors.
Synapse has enriched 10 related papers. Consider them for comparative context: